Your browser doesn't support javascript.
loading
International trends in clozapine use: a study in 17 countries.
Bachmann, C J; Aagaard, L; Bernardo, M; Brandt, L; Cartabia, M; Clavenna, A; Coma Fusté, A; Furu, K; Garuoliené, K; Hoffmann, F; Hollingworth, S; Huybrechts, K F; Kalverdijk, L J; Kawakami, K; Kieler, H; Kinoshita, T; López, S C; Machado-Alba, J E; Machado-Duque, M E; Mahesri, M; Nishtala, P S; Piovani, D; Reutfors, J; Saastamoinen, L K; Sato, I; Schuiling-Veninga, C C M; Shyu, Y-C; Siskind, D; Skurtveit, S; Verdoux, H; Wang, L-J; Zara Yahni, C; Zoëga, H; Taylor, D.
Afiliação
  • Bachmann CJ; Freelance Researcher, Marburg, Germany.
  • Aagaard L; Life Science Team, Bech-Bruun Law Firm, Copenhagen, Denmark.
  • Bernardo M; Barcelona Clinic Schizophrenia Unit, Neuroscience Institute, and Hospital Clínic, Department of Medicine, Barcelona University, and Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain.
  • Brandt L; Centre for Pharmacoepidemiology, Department of Medicine, Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Cartabia M; Pharmacoepidemiology Unit, Department of Public Health, IRCCS Istituto di Ricerche Farmacologiche 'Mario Negri', Milan, Italy.
  • Clavenna A; Pharmacoepidemiology Unit, Department of Public Health, IRCCS Istituto di Ricerche Farmacologiche 'Mario Negri', Milan, Italy.
  • Coma Fusté A; Pharmacy Department of Barcelona Health Region, Catalan Health Service (CatSalut), Barcelona, Spain.
  • Furu K; Division of Mental and Physical Health, Norwegian Institute of Public Health, Oslo, Norway.
  • Garuoliené K; Medicines Reimbursement Department, National Health Insurance Fund of the Republic of Lithuania, Vilnius, Lithuania.
  • Hoffmann F; Faculty of Medicine, Department of Pathology, Forensic Medicine and Pharmacology, Vilnius University, Vilnius, Lithuania.
  • Hollingworth S; Department of Health Services Research, Carl von Ossietzky University Oldenburg, Oldenburg, Germany.
  • Huybrechts KF; School of Pharmacy, University of Queensland, Woolloongabba, Qld, Australia.
  • Kalverdijk LJ; Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Kawakami K; University of Groningen, University Medical Center Groningen, Department of Psychiatry, the Netherlands.
  • Kieler H; Department of Pharmacoepidemiology and Clinical Research Management, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan.
  • Kinoshita T; Centre for Pharmacoepidemiology, Department of Medicine, Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • López SC; Department of Pharmacoepidemiology and Clinical Research Management, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan.
  • Machado-Alba JE; Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia, Universidad Tecnológica de Pereira - Audifarma S.A., Pereira, Colombia.
  • Machado-Duque ME; Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia, Universidad Tecnológica de Pereira - Audifarma S.A., Pereira, Colombia.
  • Mahesri M; Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia, Universidad Tecnológica de Pereira - Audifarma S.A., Pereira, Colombia.
  • Nishtala PS; Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Piovani D; New Zealand's National School of Pharmacy, University of Otago, Dunedin, New Zealand.
  • Reutfors J; Pharmacoepidemiology Unit, Department of Public Health, IRCCS Istituto di Ricerche Farmacologiche 'Mario Negri', Milan, Italy.
  • Saastamoinen LK; Centre for Pharmacoepidemiology, Department of Medicine, Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Sato I; Kela Research, The Social Insurance Institution, Helsinki, Finland.
  • Schuiling-Veninga CCM; Department of Pharmacoepidemiology and Clinical Research Management, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan.
  • Shyu YC; Unit of Pharmacotherapy, -Epidemiology and -Economics, Department of Pharmacy, University of Groningen, Groningen, the Netherlands.
  • Siskind D; Community Medicine Research Center, Chang Gung Memorial Hospital, Keelung, Taiwan.
  • Skurtveit S; Institute of Molecular Biology, Academia Sinica, Taipei, Qld, Taiwan.
  • Verdoux H; Department of Nutrition, Chang Gung University of Science and Technology, Kwei-Shan, Taiwan.
  • Wang LJ; School of Medicine, University of Queensland, Woolloongabba, Qld, Australia.
  • Zara Yahni C; Division of Mental and Physical Health, Norwegian Institute of Public Health, Oslo, Norway.
  • Zoëga H; University Bordeaux, INSERM, Bordeaux Population Health Research Center, team Pharmaco-epidemiology, UMR 1219, F-33000, Bordeaux, France.
  • Taylor D; Department of Child & Adolescent Psychiatry, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Acta Psychiatr Scand ; 136(1): 37-51, 2017 07.
Article em En | MEDLINE | ID: mdl-28502099

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Prescrições de Medicamentos / Antipsicóticos / Clozapina / Uso de Medicamentos Tipo de estudo: Clinical_trials / Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Child / Humans / Middle aged Idioma: En Revista: Acta Psychiatr Scand Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Prescrições de Medicamentos / Antipsicóticos / Clozapina / Uso de Medicamentos Tipo de estudo: Clinical_trials / Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Child / Humans / Middle aged Idioma: En Revista: Acta Psychiatr Scand Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Alemanha